MoonROSE: CDK2/4/6 Inhibitor GDC-4198 in Combination with Giredestrant for Patients with ER+, HER2- Metastatic Breast Cancer After Treatment with a CDK4/6 Inhibitor
Condition: Breast Cancer
Sponsor: Genentech, Inc.
Full Title
Protocol GO46021: A Phase Ib/II Multicenter, Open-label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer Who Have Previously Progressed During Or After a CDK4/6 Inhibitor
Study Treatment
Oral CDK2/4/6 inhibitor GDC-4198 as monotherapy or in combination with oral next generation SERD Giredestrant
Eligibility/Info
Eligible patients must have metastatic ER+, HER2- breast cancer that has been treated with a CDK4/6 inhibitor in the metastatic setting but has not been treated with chemotherapy in the metastatic setting.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Need More Information?
Our team is here to help answer your questions and guide you through your options.